Takeda, Twist partner on biologics discovery

By The Science Advisory Board staff writers

July 9, 2020 -- Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies in Takeda's biologics pipeline.

Under the agreement, Twist Biopharma will license Takeda its "Library of Libraries," a panel of synthetic antibody phage display libraries derived from human genetic sequences. Together, the companies will work to discover, validate, and optimize new antibody candidates for applications in oncology, rare diseases, neuroscience, and gastroenterology. Takeda will pay Twist annual technology licensing fees, as well as milestone payments and royalties for all compounds discovered from using Twist's phage display libraries.

Copyright © 2020 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.